Clinical Trials Logo

Clinical Trial Summary

This aims to investigated the short-term (12, 16, and 20 h) effects of 0.01% atropine (0.1 mg/ml) on pupil size and subjective quality of vision in participants with myopia. Particpants will receive 0.01% atropine one drop to both eyes before bedtime. Baseline parameters were measured before atropine application. Changes in pupil sizes, under photopic and mesopic conditions, high-order aberration, and tear meniscus height were observed over the next day (12, 16, and 20 h).


Clinical Trial Description

The utilisation of atropine drops is a common practise in order to induce pupil dilatation, impede accommodation, and decelerate the advancement of myopia. Research findings indicate that the treatment of atropine at a low concentration of 0.01% has been observed to effectively slow down the advancement of myopia, with a reduction rate ranging from 60% to 83%. The administration of a lesser dose of atropine demonstrates a decreased occurrence of undesirable effects in comparison to the administration of atropine at a high concentration of 1.0%. Nevertheless, it is crucial to acknowledge that even when present in low concentrations, atropine still exerts an influence on both pupil size and pupil responsiveness. This investigation employs a prospective cohort study design, in which a set of objective and subjective assessments will be carried out before and after the injection of 0.01% atropine for a duration of 18 hours. The main aim of this study is to determine the effects of a specific concentration of atropine on several factors, including: 1) visual acuity; 2) pupil diameter; 3) subjective perception of vision quality; and 4) intraocular pressure. The objective of this study is to examine the effects of the eye drops on ocular health and determine the degree of patient acceptance about their prospective use as a preventive measure for myopia. The researchers have a positive expectation that the administration of the drops will have minimal influence on the participants in terms of side effects. However, the outcomes of this study will provide valuable insights for children and patients in effectively managing the side effects associated with the use of atropine for myopia control. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06071260
Study type Interventional
Source He Eye Hospital
Contact
Status Not yet recruiting
Phase N/A
Start date December 1, 2023
Completion date December 20, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05919654 - Clinical Evaluation of MyoCare in Europe (CEME) N/A
Recruiting NCT03402100 - Eye Drops Study for Myopia Control in Schoolchildren N/A
Recruiting NCT03865160 - Low-dose Atropine for Myopia Control in Children Phase 2/Phase 3
Recruiting NCT06088225 - Myopia Preventing With Distance-image Screen N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Not yet recruiting NCT06405711 - To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia N/A
Recruiting NCT05881655 - Slow Myopia Progression With Different Irradiance Light N/A
Recruiting NCT05761379 - Clinical Study of Light Therapy to Control Myopia Progression in Children N/A
Not yet recruiting NCT05760911 - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches N/A
Recruiting NCT04722874 - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control N/A
Not yet recruiting NCT06221592 - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses N/A
Completed NCT04806763 - Myopia Control With Orthokeratology Contact Lenses in Spain N/A
Completed NCT04806698 - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia N/A
Completed NCT04806711 - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children N/A
Recruiting NCT05894382 - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control N/A
Completed NCT05683535 - Adverse Events Related to Low Dose Atropine
Completed NCT05300321 - DIMS-myopia Progression ADN Axial Length Growth N/A
Withdrawn NCT03519490 - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? N/A
Completed NCT05372991 - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop Phase 1/Phase 2
Active, not recruiting NCT05373693 - Myopia-control Efficacy by Peripheral Defocus Lens (PDL) N/A